Hiroki Sato1, Chihiro Fushimi2, Takuro Okada2, Takashi Matsuki3, Takahito Kondo4, G O Omura5, Kouki Miura2, Taku Yamashita3, Isaku Okamoto6, Kiyoaki Tsukahara6. 1. Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan satohiro@tokyo-med.ac.jp. 2. Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan. 3. Department of Otorhinolaryngology-Head and Neck Surgery, Kitasato University School of Medicine, Kanagawa, Japan. 4. Department of Otolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan. 5. Department of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan. 6. Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Abstract
BACKGROUND/AIM: Nivolumab, an anti-PD-1 inhibitor, has demonstrated efficacy in patients with several types of recurrent and metastatic (R/M) squamous cell carcinoma of the head and neck. We evaluated patients with R/M-NPC receiving nivolumab. PATIENTS AND METHODS: Twelve patients with R/M-NPC were enrolled at 4 institutions. The primary endpoint was overall survival, and secondary endpoints were i) progression-free survival (PFS), ii) overall response rate (ORR), iii) disease control rate (DCR), and iv) treatment-related toxicity. RESULTS: The 1-year survival rate was 75.8%, the median PFS was 2.8 months, and the 1-year PFS rate was 33.3%. The best therapeutic response was complete response in 2, stable disease in 3 and progressive disease in 7 patients. The ORR of all patients was 16.7% and the DCR was 41.7%. CONCLUSION: Nivolumab is a useful and relatively safe second-line systemic therapy in patients with R/M-NPC, and even patients who do not respond to nivolumab may survive for a long time. Copyright
BACKGROUND/AIM: Nivolumab, an anti-PD-1 inhibitor, has demonstrated efficacy in patients with several types of recurrent and metastatic (R/M) squamous cell carcinoma of the head and neck. We evaluated patients with R/M-NPC receiving nivolumab. PATIENTS AND METHODS: Twelve patients with R/M-NPC were enrolled at 4 institutions. The primary endpoint was overall survival, and secondary endpoints were i) progression-free survival (PFS), ii) overall response rate (ORR), iii) disease control rate (DCR), and iv) treatment-related toxicity. RESULTS: The 1-year survival rate was 75.8%, the median PFS was 2.8 months, and the 1-year PFS rate was 33.3%. The best therapeutic response was complete response in 2, stable disease in 3 and progressive disease in 7 patients. The ORR of all patients was 16.7% and the DCR was 41.7%. CONCLUSION:Nivolumab is a useful and relatively safe second-line systemic therapy in patients with R/M-NPC, and even patients who do not respond to nivolumab may survive for a long time. Copyright
Authors: Scott Gettinger; Leora Horn; David Jackman; David Spigel; Scott Antonia; Matthew Hellmann; John Powderly; Rebecca Heist; Lecia V Sequist; David C Smith; Philip Leming; William J Geese; Dennis Yoon; Ang Li; Julie Brahmer Journal: J Clin Oncol Date: 2018-03-23 Impact factor: 44.544
Authors: Chiun Hsu; Se-Hoon Lee; Samuel Ejadi; Caroline Even; Roger B Cohen; Christophe Le Tourneau; Janice M Mehnert; Alain Algazi; Emilie M J van Brummelen; Sanatan Saraf; Pradeep Thanigaimani; Jonathan D Cheng; Aaron R Hansen Journal: J Clin Oncol Date: 2017-08-24 Impact factor: 44.544
Authors: Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: Brigette B Y Ma; Wan-Teck Lim; Boon-Cher Goh; Edwin P Hui; Kwok-Wai Lo; Adam Pettinger; Nathan R Foster; Jonathan W Riess; Mark Agulnik; Alex Y C Chang; Akhil Chopra; Julie A Kish; Christine H Chung; Douglas R Adkins; Kevin J Cullen; Barbara J Gitlitz; Dean W Lim; Ka-Fai To; K C Allen Chan; Y M Dennis Lo; Ann D King; Charles Erlichman; Jun Yin; Brian A Costello; Anthony T C Chan Journal: J Clin Oncol Date: 2018-03-27 Impact factor: 50.717
Authors: Astrid De Meulenaere; Tijl Vermassen; David Creytens; Stijn De Keukeleire; Tim Delahaye; Philippe Deron; Fréderic Duprez; Samson Fung; Patrick Pauwels; Liesbeth Ferdinande; Sylvie Rottey Journal: Clin Transl Sci Date: 2021-10-27 Impact factor: 4.689